Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27051190 | 1.00 | ALDH1A1 (0.56) | ALDH1A1LMNAAPOBEC3AAPOBEC3GTSHR | |
| SCHEMBL1263888 | 1.00 | ALDH1A1 (0.56) | ALDH1A1LMNAAPOBEC3AAPOBEC3GTSHR | |
| SCHEMBL11235634 | 1.00 | ALDH1A1 (0.56) | ALDH1A1LMNAAPOBEC3AAPOBEC3GTSHR | |
| SCHEMBL11219530 | 1.00 | ALDH1A1 (0.56) | ALDH1A1LMNAAPOBEC3AAPOBEC3GTSHR | |
| SCHEMBL52919 | 1.00 | ALDH1A1 (0.56) | ALDH1A1LMNAAPOBEC3AAPOBEC3GTSHR | |
| SCHEMBL14674017 | 1.00 | ALDH1A1 (0.56) | ALDH1A1LMNAAPOBEC3AAPOBEC3GTSHR | |
| SCHEMBL535694 | 1.00 | ALDH1A1 (0.56) | ALDH1A1LMNAAPOBEC3AAPOBEC3GTSHR | |
| SCHEMBL535182 | 1.00 | ALDH1A1 (0.56) | ALDH1A1LMNAAPOBEC3AAPOBEC3GTSHR | |
| SCHEMBL1264640 | 1.00 | ALDH1A1 (0.56) | ALDH1A1LMNAAPOBEC3AAPOBEC3GTSHR | |
| SCHEMBL19637930 | 0.98 | ALDH1A1 (0.54) | ALDH1A1LMNAAPOBEC3AAPOBEC3GTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0355617-A1 | Process for the manufacture of benzopyran derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1990-02-28 | — | — | EP | claimed |
| JP-2108684-A | — | — | None | — | — | JP | disclosed |
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2023-11-23 | — | — | US | disclosed |
| CN-115286523-A | Preparation and use of lipid molecules and compositions thereof for the delivery of active ingredients | 中国科学院基础医学与肿瘤研究所(筹) | 2022-11-04 | — | — | CN | disclosed |
| EP-3162799-B1 | FLUOROALKYLATING AGENT | KUMIAI CHEMICAL INDUSTRY CO (JP) | 2021-03-10 | — | — | EP | disclosed |
| EP-3162799-B1 | FLUOROALKYLATING AGENT | KUMIAI CHEMICAL INDUSTRY CO (JP) | 2021-03-10 | — | — | EP | disclosed |
| US-10696640-B2 | Fluoroalkylating agent | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2020-06-30 | — | — | US | disclosed |
| US-10696640-B2 | Fluoroalkylating agent | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2020-06-30 | — | — | US | disclosed |
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-5434186-A | Antiinflammatory agents | HOFFMANN-LA ROCHE INC. (US) | 1995-07-18 | — | — | US | disclosed |
| WO-1994015900-A1 | ANTI-ANDROGENIC CYCLO AND BICYCLO ALKENES | LAFOR LABORATORIES LIMITED (US) | 1994-07-21 | — | — | WO | disclosed |
| US-5273999-A | A 4-keto-boroalkyleneoxychroman or 2,3-dihydrobenzofuran derivative | HOFFMANN-LA ROCHE INC. (US) | 1993-12-28 | — | — | US | disclosed |
| US-5264619-A | Anti-androgenic cyclo and bicyclo alkenes | LAFOR LABORATORIES LIMITED (US) | 1993-11-23 | — | — | US | disclosed |
| CN-1071423-A | BICYCLIC CARBOXYLIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 1993-04-28 | — | — | CN | disclosed |
| EP-0531823-A1 | Bicyclic carboxylic acid derivatives as anti-inflammatory agents | F. HOFFMANN-LA ROCHE AG (CH) | 1993-03-17 | — | — | EP | disclosed |
| US-5003090-A | Chemical Intermediates | HOFFMANN-LA ROCHE INC. (US) | 1991-03-26 | — | — | US | disclosed |
| US-4931574-A | Process for the preparation of benzopyrans | HOFFMANN-LA ROCHE INC. (US) | 1990-06-05 | — | — | US | disclosed |
| JP-H02108684-A | PRODUCTION OF BENZOPYRAN DERIVATIVE | F HOFFMANN LA ROCHE AG | 1990-04-20 | — | — | JP | disclosed |
| EP-0355617-A1 | Process for the manufacture of benzopyran derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | ALDH1A1 3592/4885LMNA 2055/4885APOBEC3A 3203/4885 |
| US-10696640-B2 | Fluoroalkylating agent | AFF1, AFF4, AFF2 | ALDH1A1 2072/4885LMNA 3147/4885APOBEC3A 3353/4885 |
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | FKBP5, FKBP1B, MALT1 | ALDH1A1 2350/4885LMNA 2857/4885APOBEC3A 2971/4885 |
| US-11833208-B2 | PLK1 selective degradation inducing compound | PLK1, BUB1B, BUB1 | ALDH1A1 3592/4885LMNA 2055/4885APOBEC3A 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.